α-synuclein
α-Syn
α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-synuclein regulates synaptic vesicle trafficking and subsequent neurotransmitter release. Genetics and neuropathology studies link α-synuclein to Parkinson's disease (PD) and other neurodegenerative disorders. Accumulation of misfolded oligomers and larger aggregates of α-synuclein defines multiple neurodegenerative diseases called synucleinopathies, but the mechanisms by which α-synuclein acts in neurodegeneration are unknown.
α-synuclein Isoform Specific Products
All Product Categories
-
α-synuclein Inhibitors
(109)
View all products
-
α-synuclein Antagonists
(2)
View all products
-
α-synuclein Activator
(1)
View all products
-
α-synuclein Modulators
(2)
View all products
-
α-synuclein Inducers
(2)
View all products
-
α-synuclein Degraders
(11)
View all products
-
α-synuclein Control
(1)
View all products
-
α-synuclein Ligands
(6)
View all products
-
α-synuclein Related Products (149)
Related Products (149)
-
α-synuclein Isoform Comparison
-
Alpinin A
0 ImagesCat. No.: HY-N16524CAS No.: 2151847-03-7Alpinin A is a diarylheptanoid found in the rhizomes of Alpinia officinarum. Alpinin A can strongly inhibit the aggregation of α-synuclein with inhibition rate of 66% at 10 μM. Alpinin A can be used for the research of neurological disease, such as Parkinson’s disease.
-
D-685
0 ImagesCat. No.: HY-149065CAS No.: 2893801-00-6D-685, a prodrug of D-520, exhibits higher in vivo anti-Parkinsonian efficacy in a reserpinized Parkinson's disease (PD) animal model than the parent D-520. D-685 reduces accumulation of human α-synuclein (α-syn) protein. D-685 exhibits facile brain penetration.
-
PROTAC α-synuclein degrader 1
0 ImagesCat. No.: HY-135999CAS No.: 2412273-73-3PROTAC α-synuclein degrader 1 is a α-synuclein PROTAC degrader that can recruit VHL. PROTAC α-synuclein degrader 1 induces ubiquitination and degradation of α-synuclein, and is applicable to researches on Parkinson's disease, Alzheimer's disease, dementia with Lewy bodies, multiple system atrophy, etc.
-
Semaglutide sodium
0 ImagesCat. No.: HY-114118CCAS No.: 2924330-56-1Semaglutide sodium is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide sodium promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide sodium also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide sodium has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide sodium can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
-
Dopal (purity>80%)
0 ImagesCat. No.: HY-121252ACAS No.: 5707-55-1Dopal (purity>80%) is a metabolite and aldehyde neurotoxin of Dopamine (HY-B0451). Dopal (purity>80%) exhibits cytotoxicity, induces α-synuclein oligomerization and aggregation, and is closely associated with the pathogenesis of Parkinson's disease. Dopal (purity>80%) can be used in research related to Parkinson's disease.
-
α-Synuclein (67-78) (human)
0 ImagesCat. No.: HY-P5043CAS No.: 2243206-99-5α-Synuclein (67-78) (human) is the 67-78 fragment of α-Synuclein. α-Synuclein (67-78) (human) promotes network activity drive and blocks KCl-induced syt1L-ab uptake.
-
Aerophobin-2
0 ImagesCat. No.: HY-130398CAS No.: 87075-23-8Aerophobin-2 is a bromine compound, which can be isolated from sponge Verongia aerophoba. Aerophobin-2 inhibits aggregation of α-synuclein (α-syn) and phosphorylated α-synuclein (pSyn), exhibits neuroprotective efficacy.
-
α-Synuclein (61-75)
0 ImagesCat. No.: HY-P3140CAS No.: 440645-08-9α-Synuclein (61-75) is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD).
-
NS163
0 ImagesCat. No.: HY-163613CAS No.: 3069546-41-1NS163 is a α-Synuclein aggregation antagonist. NS163 can be used for study of Parkinson’s disease.
-
CLR01 sodium
0 ImagesCat. No.: HY-182304CAS No.: 1338489-62-5CLR01 sodium is a blood-brain barrier-permeable anti-aggregation agent. CLR01 sodium inhibits the de novo aggregation of Amyloid-β 40/42, α-synuclein, IAPP, tau protein and SOD1. CLR01 sodium reduces amyloid plaque burden in the cortex of triple-transgenic mice and improves the memory and motor abilities of these mice. CLR01 sodium can be used in research related to Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).
-
α-Synuclein inhibitor 14
0 ImagesCat. No.: HY-N15613CAS No.: 408324-13-0α-Synuclein inhibitor 14 (Compound 3) is a diarylheptanoid that can be isolated from Alpinia officinarum. α-Synuclein inhibitor 14 can inhibit the aggregation of α-synuclein, with an inhibition rate of 72.4% at a concentration of 10 μM. α-Synuclein inhibitor 14 can be used in the research of neurodegenerative diseases such as Parkinson's disease.
-
Arg-PEG1-Tαsyn
0 ImagesCat. No.: HY-180976Arg-PEG1-Tαsyn is an α-syn PROTAC degrader with a DC50 of 0.28 μM in U251 cells. Arg-PEG1-Tαsyn employs the amino acid arginine (Arg) as the E3 ligase UBR1 ligand and a benzothiazole-aniline variant as the warhead for α-syn. Arg-PEG1-Tαsyn significantly reduces α-syn aggregates and improves the dopaminergic neuronal impairment and the locomotion with safety profile in vivo.Arg-PEG1-Tαsyn shows the high degradation effect in mammalian cells for both wild-type α-syn and the α-syn (A53T) mutant. Arg-PEG1-Tαsyn can be used for Parkinson’s disease research.
-
KAC-50.1
0 ImagesCat. No.: HY-168647KAC-50.1 is an α-Synuclein (α-syn) PET ligand, with a KD of 35 nM toward site 2 in recombinant α-syn fibrils.
-
Multi-kinase-IN-14
0 ImagesCat. No.: HY-181046CAS No.: 2201083-51-2Multi-kinase-IN-14 is an orally active and blood-brain barrier-permeable multi-kinase inhibitor. Multi-kinase-IN-14 reduces the excessive phosphorylation of α-synuclein by inhibiting four kinases (ABL1, DYRK1A, GSK3β, and LRRK2) and stabilizing microtubules. Multi-kinase-IN-14 is applicable for research on neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease.
-
α-Synuclein-IN-24
0 ImagesCat. No.: HY-184819CAS No.: 2883627-56-1α-Synuclein-IN-24 is an α-synuclein (α-Syn) aggregation inhibitor with an IC50 of 4.0 μM. α-Synuclein-IN-24 stabilizes the secondary conformation of α-synuclein monomers, inhibits β-sheet formation, reduces oligonucleation during the aggregation lag phase, dissociates preformed aggregates, and blocks reaggregation. α-Synuclein-IN-24 reduces α-synuclein inclusions in neuronal cells and scavenges ROS. α-Synuclein-IN-24 can be used for the research of Parkinson's disease.
-
Sulfamerazine (Standard)
0 ImagesSulfamerazine (Standard) is the analytical standard of Sulfamerazine. This product is intended for research and analytical applications. Sulfamerazine (RP2632) is a brain-penetrant and orally active sulfonamide antibiotic and α-synuclein inhibitor with human α-synuclein KD of 352 μM. Sulfamerazine inhibits the synthesis of dihydrofolate by bacteria, thereby inhibiting bacterial growth. Sulfamerazine inhibits α-synuclein fibrillation, reduces α-synuclein aggregation-associated toxicity and α-synuclein aggregate accumulation. Sulfamerazine can be used for the research of Parkinson’s disease and bacterial infection.
-
Harmol (Standard)
0 ImagesHarmol (Standard) is the analytical standard of Harmol (HY-107811). This product is intended for research and analytical applications. Harmol hydrochloride is an orally active β-carboline alkaloid. Harmol hydrochloride is a TFEB activator and monoamine oxidase inhibitor. Harmol can induce cell mitosis, Autophagy and Apoptosis. Harmol promotes the degradation of α-synuclein by regulating the autophagy-lysosomal pathway. Harmol has anti-tumor, anti-depressant and anti-aging activities. Harmol improves motor impairment in a mouse Parkinson's disease model.
-
α-Synuclein-IN-25
0 ImagesCat. No.: HY-184847CAS No.: 2883627-66-3α-Synuclein-IN-25 is a quinone-acid hybrid and also an α-synuclein aggregation inhibitor with an IC50 of 3.0 μM. α-Synuclein-IN-25 dissociates preformed α-Syn aggregates, inhibits their re-aggregation, scavenges reactive oxygen species, and reduces the formation of α-Syn inclusions in neuronal cells. α-Synuclein-IN-25 can be used in the research of Parkinson's disease.
-
NAB2 (Standard)
0 ImagesCat. No.: HY-110174RCAS No.: 1504588-00-4NAB2 (Standard) is the analytical standard of NAB2 (HY-110174). This product is intended for research and analytical applications. NAB2 is a neuroprotectant that targets the small GTPase Rab1a. NAB2 selectively binds to the GDP-bound form of Rab1a and protects multiple cell types from α-synuclein toxicity by increasing Rab1a expression. Rab1a regulates ER-to-Golgi trafficKing and mediates endosomal trafficKing events of the E3 ubiquitin ligase Rsp5/Nedd4. NAB2 stimulates ubiquitination of related proteins in a Nedd4-dependent manner and rescues α-synuclein-associated trafficKing defects associated with early-onset ParKinson's disease.
-
α-Synuclein-IN-22
0 ImagesCat. No.: HY-184817CAS No.: 2883627-63-0α-Synuclein-IN-22 is an α-Synuclein inhibitor with an IC50 of 2.7 μM against human α-Syn. α-Synuclein-IN-22 exerts anti-aggregation effects by stabilizing the native conformation of α-Syn, inhibiting the formation of β-sheet aggregates and inclusion bodies, and dissociating mature fibrils into functional monomers. α-Synuclein-IN-22 scavenges ROS and shows low cytotoxicity. α-Synuclein-IN-22 can be used in research related to Parkinson's disease.
